CoChat

In vivo anti-tumor activity of the PARP inhibitor niraparib in homologous recombination deficient and proficient ovarian carcinoma

Open access
AlHilli, Mariam M., Becker, Marc A., Weroha, S. John, Flatten, Karen S., Hurley, Rachel M., Harrell, Maria I., Oberg, Ann L., Maurer, Matt J., Hawthorne, Kieran M., Hou, Xiaonan, Harrington, Sean C., McKinstry, Sarah, Meng, X. Wei, Wilcoxen, Keith M., Kalli, Kimberly R., Swisher, Elizabeth M., Kaufmann, Scott H., Haluska, Paul · 2016 · Gynecologic Oncology
Cited by 73

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

Objective Poly(ADP-ribose) polymerase (PARP) inhibitors have yielded encouraging responses in high-grade serous ovarian carcinomas (HGSOCs), but the optimal treatment setting remains unknown. We assessed the effect of niraparib on HGSOC patient-derived xenograft (PDX) models as well as the relationship between certain markers of homologous recombination (HR) status, including BRCA1/2 mutations and formation of RAD51 foci after DNA damage, and response of these PDXs to niraparib in vivo. Methods Massively parallel sequencing was performed on HGSOCs to identify mutations contributing to HR deficiency. HR pathway integrity was assessed using fluorescence microscopy-based RAD51 focus formation assays. Effects of niraparib (MK-4827) on treatment-naïve PDX tumor growth as monotherapy, in combination with carboplatin/paclitaxel, and as maintenance therapy were assessed by transabdominal ultrasound. Niraparib responses were correlated with changes in levels of poly(ADP-ribose), PARP1, and repair proteins by western blotting. Results Five PDX models were evaluated in vivo. Tumor regressions were induced by single-agent niraparib in one of two PDX models with deleterious BRCA2 mutations and in a PDX with RAD51C promoter methylation. Diminished formation of RAD51 foci failed to predict response, but Artemis loss was associated with resistance. Niraparib generally failed to enhance responses to carboplatin/paclitaxel chemotherapy, but maintenance niraparib therapy delayed progression in a BRCA2-deficient PDX. Conclusions Mutations in HR genes are neither necessary nor sufficient to predict response to niraparib. Assessment of repair status through multiple complementary assays is needed to guide PARP inhibitor therapy, design future clinical trials and identify ovarian cancer patients most likely to benefit from PARP inhibition.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ygyno.2016.08.328

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 73

Metadata

Authors
AlHilli, M. M., Becker, M. A., Weroha, S. J., Flatten, K. S., Hurley, R. M., Harrell, M. I., Oberg, A. L., Maurer, M. J., Hawthorne, K. M., Hou, X., Harrington, S. C., McKinstry, S., Meng, X. W., Wilcoxen, K. M., Kalli, K. R., Swisher, E. M., Kaufmann, S. H., & Haluska, P.
Venue
Gynecologic Oncology
Publisher
Elsevier BV
Published
2016-11
Volume
143
Issue
2
Pages
379-388
ISSN
0090-8258 (ISSN-L)
OpenAlex
W2514437732
Cited by
73
References
4
FWCI
3.71
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: In vivo anti-tumor activity of the PARP inhibitor niraparib in homologous recombination deficient and proficient ovarian carcinoma. https://app.cochat.ai/papers/10.1016/j.ygyno.2016.08.328
The paper
AlHilli, M. M., Becker, M. A., Weroha, S. J., Flatten, K. S., Hurley, R. M., Harrell, M. I., Oberg, A. L., Maurer, M. J., Hawthorne, K. M., Hou, X., Harrington, S. C., McKinstry, S., Meng, X. W., Wilcoxen, K. M., Kalli, K. R., Swisher, E. M., Kaufmann, S. H., & Haluska, P. (2016). In vivo anti-tumor activity of the PARP inhibitor niraparib in homologous recombination deficient and proficient ovarian carcinoma. Gynecologic Oncology. https://doi.org/10.1016/j.ygyno.2016.08.328

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.